Animal virology

Team of International Scientists Identify Common Vulnerabilities Across SARS-CoV-2, SARS-CoV-1 and MERS Coronaviruses

Retrieved on: 
Thursday, October 15, 2020

These common pathways and protein targets represent high-priority targets for therapeutic interventions for this and future pandemics.

Key Points: 
  • These common pathways and protein targets represent high-priority targets for therapeutic interventions for this and future pandemics.
  • In our latest study, we augmented our knowledge base by driving down into two additional coronaviruses, elucidating mechanisms across viruses that allow potential therapeutic interventions.
  • After more than a century of relatively harmless coronaviruses, in the last 20 years we have had three coronaviruses which have been deadly.
  • Krogan, Rezelj and Jeremy Rassen of Aetion, who will review findings from their research, can be accessed here .

America’s Top Young Scientist of 2020: 14-Year-Old Researches Spike Protein of SARS-CoV-2 Virus to Develop Novel Antiviral Drug to Combat Spread of COVID-19

Retrieved on: 
Wednesday, October 14, 2020
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201014005340/en/
    Anika Chebrolu named America's Top Young Scientist at this years 3M Young Scientist Challenge (Photo: 3M).
  • With the virus continuing to spread far and wide, there is an urgent need to find an effective anti-coronavirus drug.
  • In her study, Anika discovered a molecule that can selectively bind to the spike protein of the SARS-CoV-2.
  • Binding and inhibiting this viral protein would potentially stop the virus entry into the cell, creating a viable drug target.

Innovative Approaches Lead to Novel Methods of Treatment for Viral Infections

Retrieved on: 
Wednesday, October 7, 2020

"It will be those first responders and those at greatest risk for death, and then eventually that will expand," he said.

Key Points: 
  • "It will be those first responders and those at greatest risk for death, and then eventually that will expand," he said.
  • Sunshine Biopharma Inc.(OTC: SBFM) just announced breaking news that, "it has screened and subsequently identified a lead compound from its library of Coronavirus protease inhibitors.
  • The compounds which were screened are based on the technology described in Sunshine Biopharma's recently filed patent application covering small molecules which can be used to treat Coronavirus infections.
  • There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness.

Innovative Approaches Lead to Novel Methods of Treatment for Viral Infections

Retrieved on: 
Wednesday, October 7, 2020

"It will be those first responders and those at greatest risk for death, and then eventually that will expand," he said.

Key Points: 
  • "It will be those first responders and those at greatest risk for death, and then eventually that will expand," he said.
  • Sunshine Biopharma Inc.(OTC: SBFM) just announced breaking news that, "it has screened and subsequently identified a lead compound from its library of Coronavirus protease inhibitors.
  • The compounds which were screened are based on the technology described in Sunshine Biopharma's recently filed patent application covering small molecules which can be used to treat Coronavirus infections.
  • There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness.

TaiGen filed US IND for its influenza antiviral TG-1000

Retrieved on: 
Sunday, October 4, 2020

TAIPEI, Taiwan, Oct. 4, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced today that it has filed an Investigational New Drug (IND) application with the US FDA for its influenza antiviral TG-1000.

Key Points: 
  • TAIPEI, Taiwan, Oct. 4, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced today that it has filed an Investigational New Drug (IND) application with the US FDA for its influenza antiviral TG-1000.
  • TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses.
  • The first US patent for TG-1000 was successfully prosecuted and granted by the United States Patent and Trademark Office on Jan 14th, 2020.
  • TaiGen Biotechnology is a leading research-based and market-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, China.

Avian influenza: EU on alert for new outbreaks

Retrieved on: 
Wednesday, September 30, 2020

The warning follows outbreaks of highly pathogenic avian influenza (HPAI) among wild and domestic birds in western Russia and Kazakhstan over the past few months.

Key Points: 
  • The warning follows outbreaks of highly pathogenic avian influenza (HPAI) among wild and domestic birds in western Russia and Kazakhstan over the past few months.
  • Northern and eastern Europe are likely to be the most vulnerable to new outbreaks given past experience.
  • The alert is included in the latest update on avian influenza in Europe and beyond.
  • The risk of transmission of avian influenza viruses to the general public in Europe remains very low.

AXIM® Biotechnologies Files Patent for Virus Binding Recombinant Protein for SARS-CoV-2 (COVID-19) and Begins Manufacturing

Retrieved on: 
Wednesday, September 30, 2020

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (AXIM Biotech, AXIM or the Company), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has filed a provisional patent for a recombinant virus binding protein (VBP) for SARS-CoV-2, the coronavirus responsible for the current COVID-19 pandemic, and is now manufacturing the VBP.

Key Points: 
  • SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (AXIM Biotech, AXIM or the Company), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has filed a provisional patent for a recombinant virus binding protein (VBP) for SARS-CoV-2, the coronavirus responsible for the current COVID-19 pandemic, and is now manufacturing the VBP.
  • Numerous studies have shown that the SARS-CoV-2s spike protein enters human host cells by locking its receptor binding domain (RBD) to proteins on the human cellsurface.
  • AXIMs laboratory tests have proven the RBD spike protein binds with the Companys novel VBP.
  • By internally developing and manufacturing this virus binding protein, AXIMs COVID-19 research team no longer needs to rely on outside protein supply to continue our research and can greatly cut down on our research costs.

Coronavirus Disease (COVID-19) Pipeline Review, H2 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 30, 2020

Coronavirus Disease - Pipeline Review, H2 2020, provides an overview of the Coronavirus Disease (Infectious Disease) pipeline landscape.

Key Points: 
  • Coronavirus Disease - Pipeline Review, H2 2020, provides an overview of the Coronavirus Disease (Infectious Disease) pipeline landscape.
  • Coronavirus Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Coronavirus Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Coronavirus Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Coronavirus Disease 2019 (COVID-19) and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Coronavirus Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference

Retrieved on: 
Monday, September 28, 2020

A live webcast of the virtual fireside chat can be accessed through the Investors section of Arbutus website at www.arbutusbio.com or directly at Live Webcast .

Key Points: 
  • A live webcast of the virtual fireside chat can be accessed through the Investors section of Arbutus website at www.arbutusbio.com or directly at Live Webcast .
  • An archived replay of the webcast will be available on the Companys website after the conference.
  • The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection.
  • Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).

COVISTAT, a Subsidiary of Ensysce Biosciences Inc, a California Based Company With a Mission to Solve the Opioid Crisis, Is Commencing Phase 1 Study of Novel COVID-19 Treatment

Retrieved on: 
Monday, September 28, 2020

Nafamostat, an ultra-potent protease inhibitor and an ingredient from Ensysces opioid overdose protection platform, is being developed as an oral treatment for COVID-19.

Key Points: 
  • Nafamostat, an ultra-potent protease inhibitor and an ingredient from Ensysces opioid overdose protection platform, is being developed as an oral treatment for COVID-19.
  • Nafamostat has a novel mechanism of action for treating COVID-19 as a potent protease inhibitor that blocks SARS-CoV-2 viral entry into host cells.
  • Because of this it has antiviral properties against other coronaviruses including the Middle East Respiratory Syndrome (MERS), SARS and now SARS-CoV-2.
  • Ensysce Biosciences is developing two new classes of opioid pain products (Trypsin Activated Abuse Protected TAAP) with overdose protection (MPAR).